SLC26A4_HUMAN,T508A,0.541,Loss of Strand (Pr = 0.27 | P = 0.01), ELME000052|ELME000335,-
SLC26A4_HUMAN,C466Y,0.365,-,-,-
SLC26A4_HUMAN,F667C,0.895,Loss of Strand (Pr = 0.27 | P = 0.01), ELME000007|ELME000162|ELME000313|PS00006|PS00008,-
SLC26A4_HUMAN,V480D,0.750,Gain of Helix (Pr = 0.34 | P = 8.9e-04); Loss of Strand (Pr = 0.32 | P = 4.8e-04); Altered Stability (Pr = 0.15 | P = 0.02), ELME000233,-
SLC26A4_HUMAN,Y536C,0.852,Altered Transmembrane protein (Pr = 0.28 | P = 6.2e-04); Altered Ordered interface (Pr = 0.28 | P = 0.04); Gain of Disulfide linkage at Y536 (Pr = 0.18 | P = 0.03), ELME000084|ELME000120,-
SLC26A4_HUMAN,N457D,0.865,Altered Transmembrane protein (Pr = 0.11 | P = 0.04), ELME000193,-
SLC26A4_HUMAN,P112S,0.601,Altered Ordered interface (Pr = 0.29 | P = 5.6e-03); Altered Transmembrane protein (Pr = 0.25 | P = 1.2e-03), ELME000239,-
SLC26A4_HUMAN,A456D,0.837,Altered Transmembrane protein (Pr = 0.13 | P = 0.02), ELME000193|ELME000333,-
SLC26A4_HUMAN,M147V,0.889,, ELME000053|ELME000148|ELME000335|ELME000336,-
SLC26A4_HUMAN,Q421L,0.901,Loss of Intrinsic disorder (Pr = 0.37 | P = 0.04); Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.26 | P = 6.9e-04); Gain of Ubiquitylation at K419 (Pr = 0.16 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), ELME000106|ELME000202,-
SLC26A4_HUMAN,A664V,0.475,-,-,-
SLC26A4_HUMAN,F692L,0.656,, ELME000182,-
SLC26A4_HUMAN,I655N,0.787,Loss of Strand (Pr = 0.30 | P = 1.9e-03); Gain of N-linked glycosylation at I655 (Pr = 0.01 | P = 0.04), ELME000070|ELME000239|PS00001,-
SLC26A4_HUMAN,E384G,0.924,Altered Metal binding (Pr = 0.52 | P = 3.8e-04); Altered Transmembrane protein (Pr = 0.30 | P = 1.5e-04); Loss of Helix (Pr = 0.30 | P = 7.7e-03); Altered Ordered interface (Pr = 0.28 | P = 0.04); Loss of Catalytic site at E384 (Pr = 0.23 | P = 8.2e-03), None,-
SLC26A4_HUMAN,S666F,0.765,Loss of Catalytic site at D661 (Pr = 0.14 | P = 0.02); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000313|PS00006,-
SLC26A4_HUMAN,V231E,0.885,Gain of Helix (Pr = 0.28 | P = 0.03); Altered Transmembrane protein (Pr = 0.14 | P = 0.02), ELME000117|ELME000202|ELME000333,-
SLC26A4_HUMAN,G595E,0.505,Altered Disordered interface (Pr = 0.46 | P = 4.1e-03); Gain of Helix (Pr = 0.27 | P = 0.03); Loss of Acetylation at K590 (Pr = 0.27 | P = 6.6e-03); Altered Coiled coil (Pr = 0.12 | P = 0.03), ELME000002|ELME000085|ELME000134|ELME000313|ELME000336|PS00008,-
SLC26A4_HUMAN,D724G,0.895,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000134|ELME000220|PS00006,-
SLC26A4_HUMAN,V653A,0.496,-,-,-
SLC26A4_HUMAN,K601N,0.501,Loss of Strand (Pr = 0.26 | P = 0.05); Altered Disordered interface (Pr = 0.19 | P = 0.04); Loss of Ubiquitylation at K601 (Pr = 0.15 | P = 0.04), ELME000062|ELME000336,-
SLC26A4_HUMAN,L458P,0.963,Loss of Helix (Pr = 0.31 | P = 4.3e-03); Altered Transmembrane protein (Pr = 0.18 | P = 8.4e-03); Altered Stability (Pr = 0.10 | P = 0.04), None,-
SLC26A4_HUMAN,L50P,0.732,Gain of Intrinsic disorder (Pr = 0.41 | P = 7.2e-03); Gain of Helix (Pr = 0.28 | P = 0.02); Altered Stability (Pr = 0.13 | P = 0.03), ELME000136|ELME000153|ELME000159|ELME000276|ELME000336,-
SLC26A4_HUMAN,G222A,0.865,Altered Transmembrane protein (Pr = 0.24 | P = 2.2e-03), PS00008,-
SLC26A4_HUMAN,G204V,0.897,Altered Transmembrane protein (Pr = 0.01 | P = 0.01), None,-
SLC26A4_HUMAN,S694P,0.660,, ELME000157|ELME000182|PS00006,-
SLC26A4_HUMAN,V306G,0.828,Gain of Helix (Pr = 0.31 | P = 5.2e-03); Altered Metal binding (Pr = 0.13 | P = 0.05), ELME000053|ELME000333|ELME000335|PS00008,-
SLC26A4_HUMAN,T420I,0.724,Loss of Intrinsic disorder (Pr = 0.41 | P = 0.02); Gain of Pyrrolidone carboxylic acid at Q421 (Pr = 0.20 | P = 1.9e-03); Loss of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), ELME000053|ELME000202,-
SLC26A4_HUMAN,D271G,0.774,Altered Transmembrane protein (Pr = 0.29 | P = 1.9e-04); Loss of Relative solvent accessibility (Pr = 0.27 | P = 0.02); Gain of GPI-anchor amidation at N268 (Pr = 0.01 | P = 0.03), ELME000052|ELME000147,-
SLC26A4_HUMAN,L68P,0.758,, ELME000106|ELME000136|ELME000159|ELME000335|ELME000358|PS00008,-
SLC26A4_HUMAN,G424D,0.827,Altered Ordered interface (Pr = 0.29 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.20 | P = 2.1e-03); Gain of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Loss of Methylation at K419 (Pr = 0.15 | P = 0.02), PS00008,-
SLC26A4_HUMAN,T404I,0.699,, ELME000052|ELME000053|ELME000336,-
SLC26A4_HUMAN,R409H,0.857,Loss of ADP-ribosylation at R409 (Pr = 0.23 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q413 (Pr = 0.04 | P = 0.04), ELME000336,-
SLC26A4_HUMAN,E414K,0.641,Gain of Methylation at E414 (Pr = 0.19 | P = 6.4e-03); Loss of Ubiquitylation at K419 (Pr = 0.17 | P = 0.03); Gain of Pyrrolidone carboxylic acid at Q413 (Pr = 0.05 | P = 0.04), ELME000053|ELME000117,-
SLC26A4_HUMAN,L506R,0.879,Gain of Strand (Pr = 0.28 | P = 0.01); Altered Stability (Pr = 0.12 | P = 0.03); Altered Transmembrane protein (Pr = 0.01 | P = 8.8e-03), ELME000052|ELME000062|PS00008,-
SLC26A4_HUMAN,A106V,0.690,Altered Transmembrane protein (Pr = 0.30 | P = 1.6e-04); Altered Ordered interface (Pr = 0.26 | P = 0.01), ELME000083|ELME000120|ELME000182|PS00008,-
SLC26A4_HUMAN,L668P,0.929,Loss of Helix (Pr = 0.29 | P = 0.01); Altered Stability (Pr = 0.19 | P = 0.01), ELME000313|PS00006,-
SLC26A4_HUMAN,H723Y,0.723,Altered Metal binding (Pr = 0.06 | P = 0.03), ELME000120|ELME000134|ELME000142|ELME000220|ELME000336|PS00006,-
SLC26A4_HUMAN,E704Q,0.327,-,-,-
SLC26A4_HUMAN,Y556H,0.779,Altered Ordered interface (Pr = 0.32 | P = 0.01); Altered DNA binding (Pr = 0.28 | P = 3.4e-03), ELME000020|ELME000084|ELME000120,-
SLC26A4_HUMAN,S28R,0.458,-,-,-
SLC26A4_HUMAN,Y105C,0.834,Altered Ordered interface (Pr = 0.53 | P = 1.1e-04); Altered Transmembrane protein (Pr = 0.31 | P = 9.7e-05); Gain of Catalytic site at Q101 (Pr = 0.09 | P = 0.04), ELME000120|PS00008,-
SLC26A4_HUMAN,Y556C,0.866,Altered Ordered interface (Pr = 0.32 | P = 0.01); Loss of Strand (Pr = 0.27 | P = 0.01); Altered DNA binding (Pr = 0.24 | P = 0.01), ELME000020|ELME000084|ELME000120,-
SLC26A4_HUMAN,T416P,0.805,Gain of B-factor (Pr = 0.26 | P = 0.02); Loss of Pyrrolidone carboxylic acid at Q421 (Pr = 0.19 | P = 2.4e-03); Loss of Ubiquitylation at K419 (Pr = 0.16 | P = 0.03); Gain of Methylation at K419 (Pr = 0.15 | P = 0.01), ELME000053|ELME000136|ELME000159,-
SLC26A4_HUMAN,F515S,0.754,Altered Ordered interface (Pr = 0.28 | P = 0.03); Loss of Pyrrolidone carboxylic acid at Q514 (Pr = 0.05 | P = 0.03); Gain of GPI-anchor amidation at N519 (Pr = 0.04 | P = 5.7e-03), ELME000136|ELME000137|ELME000155|ELME000159|ELME000173,-
SLC26A4_HUMAN,P297Q,0.459,-,-,-
SLC26A4_HUMAN,V233L,0.487,-,-,-
SLC26A4_HUMAN,E303Q,0.831,Loss of Helix (Pr = 0.28 | P = 0.02); Gain of Strand (Pr = 0.26 | P = 0.04); Altered Transmembrane protein (Pr = 0.10 | P = 0.04), ELME000335,-
SLC26A4_HUMAN,I455F,0.864,Altered Transmembrane protein (Pr = 0.12 | P = 0.03), None,-
SLC26A4_HUMAN,L597S,0.655,Gain of Intrinsic disorder (Pr = 0.31 | P = 0.04); Altered Disordered interface (Pr = 0.27 | P = 0.01); Loss of Helix (Pr = 0.27 | P = 0.04); Loss of Acetylation at K593 (Pr = 0.26 | P = 0.01), ELME000062|ELME000063|ELME000134|ELME000313|ELME000336|PS00008,-
SLC26A4_HUMAN,G6V,0.122,-,-,-
